Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Chemotherapy for Bladder Sparing in MIBC
NCT04909775Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in muscle-invasive bladder cancer (MIBC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04909775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909775.